Therapixel, a Nice, Paris-France- and Chicago, IL-based designer and supplier of MammoScreen® an Artificial Intelligence software reading aid for mammography, announced that it raised €15 million in Series B funding.
The round was led by Crédit Mutuel Innovation and CapHorn, joined by Verve Ventures, Sham Innovation Santé and historical investors Omnes, IT-Translation, M-Capital and Région Sud Investissement.
This fundraising will enable Therapixel to accelerate its commercial presence in the United States, launch more unique features for MammoScreen, and push even further the boundaries of its intelligent reading aid for mammography.
Company: Therapixel SA
Round: Series B
Funding Month: May 2022
Lead Investors: Crédit Mutuel Innovation and CapHorn
Additional Investors: Verve Ventures, Sham Innovation Santé and historical investors Omnes, IT-Translation, M-Capital and Région Sud Investissement
Company Website: https://www.therapixel.com/
Software Category: AI-powered Medical Imaging Software
About the Company: Therapixel is a French company that specialized in the design and commercialization of AI-powered medical imaging software, to deliver pertinent information at the right time to healthcare professionals. Winner of the Digital Mammography DREAM Challenge in 2017, the global competition on breast cancer detection with AI, Therapixel has developed MammoScreen®, a software that helps with the interpretation of screening 2D and 3D mammograms. With MammoScreen, even experienced radiologists can improve their performance, feel more confident in their judgment, and reassure women quicker.